证券代码：688091 证券简称：上海谊众 公告编号：2025-027 上海谊众药业股份有限公司 股东询价转让计划书 上海凯宝药业股份有限公司（以下简称"上海凯宝"或"出让方"）保证向 上海谊众药业股份有限公司（以下简称"公司"或"上海谊众"）提供的信息内容不 存在任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性和完整性 依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 序号 | 拟参与转让股东的名称 | 持股数量（股） | 持股占总股本比例 | | --- | --- | --- | --- | | 1 | 上海凯宝 | 24,703,546 | 11.95% | 注：以上持股比例按 2025 年 7 月 16 日公司总股本 206,703,640 股计算。 （二）关于出让方是否为上海谊众控股股东、实际控制人、持股 5%以上的 股东、董事及高级管理人员 本次询价转让的出让方持有上海谊众的股份比例超过 5%，非公司控股股东、 实际控制人及其一致行动人，非公司董事、高级管理人员。 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 ...

沪深两市全天主力资金净流出381.11亿元，其中，科创板主力资金净流出9.78亿元，主力资金净流入的 有259只股，主力资金净流出的有330只股。 证券时报•数据宝统计显示，今日科创板个股上涨的有358只，涨停的有上纬新材、之江生物等2只，下 跌的有219只。其中，上市5日内的有屹唐股份等，今日跌幅较高的有屹唐股份，跌幅为1.86%。 从主力资金连续性进行观察，共有53只个股主力资金连续3个交易日以上持续净流入，连续净流入天数 最多的是龙软科技、天德钰等2只股，主力资金均连续净流入6天。主力资金连续流出的个股有125只， 连续流出天数最多的是广大特材，该股已连续16个交易日净流出；连续净流出天数较多的还有南芯科 技、*ST观典等，主力资金分别连续流出14天、11天。（数据宝） 主力资金净流入排名 | 代码 | 简称 | 主力资金净流入（万元） | 主力资金流入率（%） | 涨跌幅（%） | 换手率（%） | | --- | --- | --- | --- | --- | --- | | 688256 | 寒武纪 | 19329.01 | 5.26 | 2.00 | 1.56 | | 688336 | 三生国健 ...

Group 1 - The concepts of CRO, weight loss drugs, and innovative drugs are experiencing a resurgence in the market [1] - Companies such as Puris, which saw a rise of over 14%, and Jizhitang, which hit the daily limit, are leading this trend [1] - Other companies like Saily Medical, Shanghai Yizhong, Yinuosi, and Aosaikan are also witnessing significant gains [1]

Core Viewpoint - The innovative drug sector experienced a rebound, with CXO direction leading the gains, as several companies saw significant stock price increases, indicating growing confidence in China's innovative drug capabilities on the international stage [1] Group 1: Market Performance - Companies such as Puris, Medici, Jiuzhitang, Sali Medical, Huanyu Pharmaceutical, and Shanghai Yizhong all reported stock price increases, with Puris rising over 10% and others exceeding 6% [1] Group 2: Industry Insights - CICC released a report highlighting that the recent disclosures of numerous clinical data at ASCO, along with significant business development (BD) deals represented by Sanofi, further confirm the international competitiveness of Chinese innovative drugs [1] - The upcoming ESMO conference and the data disclosures surrounding it are expected to positively catalyze the innovative drug sector [1]

Core Viewpoint - The A-share innovative drug sector experienced a significant surge on July 1, driven by favorable policy announcements from the National Medical Insurance Administration and the National Health Commission, which aim to support the high-quality development of innovative drugs [1][4]. Group 1: Market Performance - Frontier Biotech reached a 20% limit-up, with other companies like Guizhou BaiLing, Saily Medical, and AngliKang also hitting their limits [2]. - Notable stock performances included: - Frontier Biotech: 12.05 (+20.02%) - Kexing Pharmaceutical: 44.19 (+15.62%) - Yuyuan Pharmaceutical: 22.00 (+15.55%) - Shuyitai: 43.00 (+15.34%) - Rongchang Biotech: 68.39 (+13.04%) [3]. Group 2: Policy Support - The new measures encourage the use of medical insurance data for innovative drug research and development, enhancing collaboration among medical, insurance, and pharmaceutical sectors [4][6]. - The policy promotes the expansion of commercial health insurance investments in innovative drugs, establishing a new directory for innovative drugs that exceed basic insurance coverage [6]. - The National Medical Insurance Administration plans to streamline the application process for including drugs in both commercial and medical insurance directories, reducing the administrative burden on companies [6]. Group 3: Industry Outlook - The innovative drug sector is in a golden development phase, with over 20 first-class innovative drugs approved for market entry from January to May, marking a five-year high [7]. - Chinese pharmaceutical companies are accelerating their international expansion, with over 90 overseas licensing transactions expected in 2024, totaling over $50 billion [7]. - Significant licensing deals include: - 12.5 billion USD deal by 3SBio - 53.3 billion USD collaboration between CSPC and AstraZeneca - 42.3 billion USD agreement by Rongchang Biotech [7]. - Several biotech firms are increasing R&D investments through share placements, with funds directed towards global R&D pipelines [8]. Group 4: Investment Sentiment - Analysts agree on the sustainable growth potential of the innovative drug sector, emphasizing the "innovation + internationalization" trend as a core focus for the pharmaceutical industry [9]. - Investment opportunities are seen in the upstream pharmaceutical supply chain, advanced manufacturing, and healthcare services, with a focus on companies with strong growth potential and profitability [9].

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) increased by 0.93% as of July 1, 2025, with notable gains from stocks such as Rongchang Biopharmaceutical (688331) up 7.21% and Shanghai Yizhong (688091) up 3.61% [1] - Starting July 1, 2025, a new policy mandates that all drug sales must include a verification code for medical insurance reimbursement, with full traceability of drug codes required by January 1, 2026, which is expected to enhance drug circulation regulation and impact the entire pharmaceutical industry chain [1] - The current bull market in innovative drugs is driven by the improvement of China's pharmaceutical innovation capabilities, with a trend towards international collaboration in new drug development expected to enhance profitability and market potential for Chinese pharmaceutical companies [2] Group 2 - As of June 30, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index accounted for 50.3% of the index, including companies like United Imaging Healthcare (688271) and BeiGene (688235) [3] - The Sci-Tech Biopharmaceutical ETF closely tracks the performance of the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which includes 50 large-cap companies in various biopharmaceutical sectors [2]

Group 1: Liquidity and Performance of Sci-Tech Pharmaceutical Index ETF - The Sci-Tech Pharmaceutical Index ETF had a turnover rate of 16.48% during the trading session, with a transaction volume of 37.98 million yuan, indicating active market trading [2] - Over the past week, the average daily transaction volume of the ETF reached 48.92 million yuan, ranking first among comparable funds [2] - In the past year, the ETF's scale increased by 154 million yuan, achieving significant growth and ranking first in new scale among comparable funds [2] - The ETF's shares grew by 130 million units in the past year, also ranking first in new shares among comparable funds [2] - As of June 10, the net value of the ETF increased by 25.51% over the past year [2] - The highest monthly return since inception was 23.29%, with the longest consecutive monthly gains being 4 months and a maximum increase of 21.76% [2] - The average monthly return during the rising months was 8.18%, with a historical one-year profit probability of 69.81% [2] Group 2: Market Trends and Investment Opportunities - The Central Committee of the Communist Party of China and the State Council issued opinions to improve the basic medical insurance drug catalog adjustment mechanism and to develop a commercial health insurance innovative drug catalog [3] - A report from Dongwu Securities indicated that there were 73 oral presentations from China at the 2025 ASCO, marking a historical high, with 89 out of 184 ADC pipeline studies coming from China, accounting for approximately 48.4% of the total [3] - The agency believes that the competitiveness of domestic innovative drugs in the global market is continuously improving, and international investors' confidence in Chinese innovative drug companies is increasing [3] - Domestic innovative drugs are transitioning from "catching up" to "leading," presenting significant investment opportunities [3] - Investors without stock accounts can access the Sci-Tech Biopharmaceutical ETF linked fund (021061) to capitalize on opportunities in the Sci-Tech Board biopharmaceutical sector [3]

证券代码：688091 证券简称：上海谊众 公告编号：2025-026 上海谊众药业股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海谊众药业股份有限公司（以下简称"公司"）于近日收到国金证券股份有 限公司（以下简称"国金证券"）发来的《关于变更持续督导保荐代表人的函》。 国金证券作为公司 2021 年首次公开发行股票并在科创板上市的保荐机构，担任 公司首次公开发行股票并上市项目持续督导工作的保荐代表人秦勤女士因工作 变动，不再负责公司首次公开发行股票并上市项目的持续督导工作。为保证公司 持续督导工作的正常进行，国金证券现委派徐清卉女士（简历后附）接替秦勤女 士，担任公司持续督导保荐代表人，继续履行持续督导的保荐职责。 此次变更后，公司首次公开发行股票并上市项目持续督导保荐代表人为顾兆 廷先生和徐清卉女士。 公司董事会对秦勤女士为公司首次公开发行股票并上市及持续督导期间所 做出的贡献表示衷心的感谢！ 特此公告。 上海谊众药业股份有限公司董事会 2025 年 6 月 10 日 ...

本次公司财务总监的变更不会影响公司正常运作与经营，新任财务总监汤节节女 士具备相关专业知识和履行财务总监职责所需的能力，能够胜任公司财务总监的履 职要求，其任职资格符合相关法律法规的要求。 特此公告。 上海谊众药业股份有限公司董事会 2025 年 6 月 7 日 证券代码：688091 证券简称：上海谊众 公告编号：2025-024 上海谊众药业股份有限公司 关于变更财务总监的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海谊众药业股份有限公司（以下简称"公司"）财务总监张芷源女士因工作内 容调整，不再担任财务总监职务，张芷源女士卸任后将担任公司内部审计负责人。 张芷源女士在担任公司财务总监期间，勤勉敬业、恪尽职守，公司及公司董事会对 张芷源女士所做出的贡献表示衷心的感谢。 根据《中华人民共和国公司法》和《上海谊众药业股份有限公司章程》的相关规 定，经公司总经理提名并经董事会提名委员会、审计委员会审议通过，公司于 2025 年 6 月 6 日召开了第二届董事会第十次会议，审议通过了《关于变更公司财务总监 的议案》 ...

证券代码：688091 证券简称：上海谊众 公告编号：2025-025 上海谊众药业股份有限公司关于 2025 年度"提质增效重回报"行动方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海谊众药业股份有限公司（以下简称"公司"或"上海谊众"）为提升经营 发展质量与践行"以投资者为本"的上市公司发展理念，响应上海证券交易所《关 于开展沪市公司"提质增效重回报"专项行动的倡议》，在生产经营、公司治理及 投资者交流与回报三个层面上进行了现状分析，制定了《上海谊众药业股份有限 公司 2025 年度"提质增效重回报"行动方案》（以下简称"行动方案"），旨在全 面提升公司的经营效率与质量，维护公司的投资价值，保护投资者尤其是中小投 资者的合法权益。具体措施内容如下： 一、 聚焦主业，在稳健经营中实现高质量发展 上海谊众致力于抗肿瘤创新药及相关产品的开发，拥有高分子材料、药物制剂、 生物学等背景的高科技人才，具备独立自主的药品研发能力与完整的药品生产系 统，是一家集研发、生产、销售为一体的高科技制药企业。 公司深耕抗肿瘤创 ...